Respiratory viruses such as influenza A, rhinoviruses and respiratory syncytial virus are transmitted from person to person predominantly by coughing virus-contaminated saliva and throat droplets (reviewed by Tyrrell, 1965; Collier & Oxford, 2002) . Moreover, such droplets can settle on surfaces, cups and doorknobs and thereby contaminate and infect another person (Gwaltney & Hendley, 1982) . Most scientific attention has been directed towards synthetic inhibitors which block the replication of viruses intracellularly and two such classes of drug(s) have been discovered with activity against influenza A, the M2 blockers and the neuraminidase inhibitors (Oxford & Galbraith, 1987; Von Itzstein et al., 1993; Kim, et al., 1997; Gubareva et al., 2000) .
At present, severe acute respiratory syndrome coronavirus (SARS-CoV)-infected patients are treated only by supportive nursing, as the efficacy of ribavirin and corticosteroids in SARS-CoV infection are unproven. Most recently, Haagmans et al. (2004) have described the effectiveness of pegylated interferon alpha on SARS-CoV in a monkey model but such studies have not been initiated in humans. However, other molecules may destroy virus extracellularly or attach to viruses and prevent subsequent adsorption. Mild detergents can disrupt lipid-enveloped viruses whereas certain externally positioned virus spikes and proteins are susceptible to configuration changes at low pH. Additionally a range of more traditional antimicrobial compounds may bind to viruses and cause inactivation.
Here we describe the inactivation in vitro of three respiratory viruses by a lozenge formulation of amyl meta cresol and dichlorobenzyl alcohol at low pH, dissolved in artificial saliva. Phenols and cresols have long been recognized as antimicrobials and have membrane-active properties, whilst alcohols also exhibit broad-spectrum antimicrobial activity (McDonnell & Russell, 1999) . A range of these molecules relieve the symptoms of sore throats (Pitts & Vincent, 1988) . However there have been relatively few virucidal investigations using specific human viruses, with the exception of microbicides against HIV (reviewed by Keller et al, 2003) . A number of sore throat lozenges, including Strepsils®, contain agents that are known to have an antibacterial effect. However, given that sore throat is a symptom of an upper respiratory tract infection and is known to be mostly associated with viral infection, it was of interest to determine whether such products exert any antiviral effect. 
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A/Beijing/ 353/89 (H3N2)] and two non-enveloped respiratory viruses (adenovirus type subgroup C and rhinovirus type 2) were propagated using standard techniques with Madin Darby canine kidney (MDCK), human HELA, or green monkey cells BSC-1. (Al-Jabri et al., 1996) . Cells were propagated in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum and 2 mM L-glutamine in 50 ml Nunc tissue culture flasks. Cells were plated into 96-well tissue culture plates and incubated at 37°C. SARS-CoV virus was cultivated in Vero cells E6 (Peiris et al., 2003a) . Virus was kindly provided by A Osterhaus, University of Rotterdam, the Netherlands. Virus endpoints were calculated from cytopathogenic changes recorded visually in duplicate cultures after incubating virus-infected cells for 5-7 days.
Virucidal test and titration for residual virus infectivity
One lozenge (2,4-dichloro benzyl alcohol 1.2 mg and amyl meta cresol 0.6 mg incorporating tartaric acid) Strepsils® was dissolved in 5 ml of artificial saliva (0.1% NaHCO 3 , 0.1% gastric mucin pH 6.0-6.5) or in DMEM.
Each virus at a known infectious titre (approximately 10
TCID 50/ml for influenza virus, 10 5.2 TCID 50/ml for RSV, 10 9 TCID 50/ml for adenovirus 10 5 TCID 50/ml for rhinovirus and 10 4.5 TCID 50/ml for SARS-CoV) was diluted 1/10 in the artificial saliva (or in medium) and incubated for 2-16 min at 37°C. Any residual virus infectivity was detected by quantitative titration in the respective cell line. A positive control in the SARS-CoV experiment was 20% ethanol and 1% tween 20 in phosphate buffered saline and in the influenza experiments 0.1% triton X-100. All experiments were performed in duplicate with equivalent results.
No cytotoxicity of the lozenge solution was observed during the titrations for residual virus infectivity which, if detected, could have altered the interpretation of residual virus infectivity.
Electron microscopy
One lozenge was dissolved in 5.0 ml of artificial saliva, while artificial saliva alone was the control. The virucidal mixture or saliva control was placed in Eppindorf tubes, and purified influenza A/USSR/90/77 (H1N1); A/Taiwan/77 (H1N1) and B/Beijing/184/93 viruses (10 mg/ml viral protein) were added and incubated as above for 1-20 minutes.
Subsequently, 100 µl of 3% glutaraldehyde/0.1M cacodylate buffer was added to each tube to stop the interaction. In another experiment, the virus was exposed to either virucidal mixture or saliva in the same way without adding glutaraldehyde. After exposure, EM grids were prepared by placing 8 µl virus suspension on a 2×2 mm agarose square, following which the grid was placed down over the suspension and allowed to remain until the fluid was absorbed through the agarose. The grid was then washed in distilled water, negatively stained with 2% sodium phosphotungstate at pH 6.0, and allowed to dry. The grids were examined in a Phillips EM301 transmission electron microscope and micrographs were taken at either 9.1 k or 45 k magnification.
Effect of the virucidical lozenge mixture on the infectivity of respiratory viruses
Incubation of influenza A virus with either the virucidal mixture or a non-ionic detergent (0.1% triton ×-100) as a control for 2 min or longer at 37°C reduced the virus infectivity to undetectable levels. Thus, the infectivity titre of the influenza virus A/Taiwan/78 (H1N1) incubated with the artificial saliva approximated to 10 5.2 TCID 50/ml . After incubation with the lozenges, this reduced to less than 1.2 log 10 TCID 50/ml (Table 1) . Similarly, after 2 min incubation at 37°C with the virucidal mixture a reduction of infectivity was detected for RSV of ≥4.0 log 10 TCID 50/ml . Greater than 3.5 log TCID 50 per ml inactivation of SARS-CoV virus was also detected (Table 1) . Virucidal activity commenced after 2 min incubation when 1.0 log 10 TCID 50 /µl of SARSCoV was destroyed. No additional virucidal effects were noted after the initial 2 min inactivation. The positive control mixture of 20% alcohol and 1% tween also inactivated SARS-CoV virus after 2 min at 37°C (≥2.5 log 20 TCID 50 ). No virucidal effects were detected after varying times of incubation (up to 16 min) at 37°C with the lozenge solution and adenovirus or rhinovirus.
Electron microscopy of influenza A viruses and the virucidal lozenge mixture
The dissolved lozenge virucide caused very significant clumping and aggregation of the influenza virus (Figures 2  and 3 ) compared to the evenly distributed control virions in the artificial saliva buffer solution (Figure 1 ). The size of the clumps varied greatly from small clumps of a few tens of influenza particles to very large masses that were too electron-dense to estimate their size. There were also some particles that were not clumped. The clumping was consistent over the time range of the experiment from 2-16 min incubation at 37°C. Essentially identical data were noted with A/USSR/90/77, A/Taiwan/77 and B/Beijing/184/93 viruses.
Another morphological effect was distortion of the morphology of the virus particles. After incubation with the lozenge for 1 min or longer at 37°C the virus spikes were indistinct and distorted (Figure 3) . The outline of the particles, usually round or fusiform (Figure 4) , became angular perhaps as the result of distortion during clumping.
The negative stain penetrated a low and equivalent proportion of virions at each of the times of incubation with the virucide or saliva control (1-16 min at 37°C), indicating no significant destructive effect on the viral lipid membrane by the virucide. Thus, quantitation of stain penetrated viruses from electron micrographs showed 78/287 penetrated virions in Strepsils®-treated virus compared to 56/259 stain penetrated virions in the control experiments.
Discussion
The study has established a virucidal destructive effect of a dissolved throat lozenge upon respiratory viruses of three distinct families, namely influenza, RSV and SARS-CoV. The virus destructive effect is rapid, occurring within 2 min of contact of the virus with the mixture at 37°C. Molecules which interact to solubilize the lipid bilayer of a virus such as cationic or non-ionic detergents would also be expected to destroy infectivity (Oxford et al., 1971 (Oxford et al., , 1994 . However, the latter molecules would be expected to cause a complete breakdown of the structure of a lipid virus such as influenza. Complete destruction of influenza virions was not visualized by electron microscopy in the present study, although we cannot exclude destruction of a minority of the virions which may not have been quantified. In contrast electron microscopy established that immediate clumping of virions occurred in the presence of the lozenge solution.
In addition, some distortion of virion morphology was detected and there was some penetration of viral membrane by the negative stain. Theoretically, there are several morphological explanations for the reduction in virus infectivity after incubation with the lozenge. Viral membrane damage by itself is not considered to be the main mode of action because there was only a low proportion of strain-penetrated virions (M Addawe, unpublished data) after incubation with the lozenge or control saliva for varying periods from 1-16 min at 37°C. Mild denaturation of the external protein spikes by χ metacresol and dichlorobenzyl alcohol may have led to clumping in the low pH conditions and may be a significant factor. The lozenge solution is at a low pH induced by tartaric acid and this could affect the structure of the influenza haemagglutinin, causing rearrangement of the protein's tertiary structure. This could, in turn, affect the infectivity of the virus and also result in virus clumping. Additionally, we cannot exclude osmotic pressure changes or stickiness induced by the sugar of the lozenge. Further studies are required to analyse the contribution of the individual constituents of the lozenge and, in particular, the effects of low pH and whether tartaric acid is an essential constituent, and also to investigate any effects of the constituents on viral replication per se.
The absence of virion-destructive effects on the nonenveloped viruses (adenoviruses and rhinoviruses) would also suggest some selective effect of the lozenge mixture on viral lipid membranes or viral protein-lipid interaction. The non-enveloped viruses are, in general, more heat and reagent stable (reviewed by Collier & Oxford, 2002) .
Of particular interest would be deductions about the clinical relevance of the in vitro studies. It has been JS Oxford et al. 132 ©2005 International Medical Press commonly observed that individuals infected with influenza virus excrete 10 3 or 10 4 influenza virions per ml of throat washing (reviewed by Stuart-Harris et al., Schild & Oxford, 1985) . It could be deduced that contact of the lozenge with these quantities of virus in the throat could cause rapid virus inactivation. The practical and clinical effect would be a potential reduction of spread of the virus to a contact. In addition, it is possible that reduction of virus infectivity titre per se in the throat could lead to a reduction in spread of the virus to the lower respiratory tract in the patient. Obviously, the lozenge would need to be administered over a period of 2 days. These clinical and virological parameters could be studied in a small pilot clinical trial with volunteer patients who have sore throats caused by influenza virus. Recently quarantine experiments with influenza A and B viruses have been recommenced in the UK [Fries et al., (2003) SARS virus RNA has been detected in saliva and sputum in high concentrations (Drosten et al., 2003 , reviewed by Oxford et al., 2003 . This finding is unique for a respiratory virus but the cell type's precise localization for virus replication has yet to be established. However, inactivation of SARS virus in sputum by a lozenge may theoretically be expected to reduce any transmission by this route.
The recent outbreaks of emerging enveloped viruses such as SARS-CoV (Peiris et al., 2003b; Lee et al., 2003) and chicken influenza A H5 and H7 (Bridges et al., 2002; Von Kolfschooten, 2003; Hien et al., 2004) viruses has highlighted how quickly new pandemics may arise. In the case of SARS-CoV, which has a low reproductive factor whereby an infected person normally infects only two or three contacts, increased hygiene and cleanliness resulted in an abrupt termination of the outbreak. However, should either virus of the Myxoviridae or Coronaviridae re-emerge, a complete armentarium of antiviral drugs (reviewed by Oxford et al., 2002) , vaccines and virucides, either for surface disinfection or as throat lozenges, may have important public health applications.
